KMT2A and leukemia: In contrast to melanoma, where CSPG4 acts as an oncogenic driver by providing growth-promoting signals and blocking apoptosis (see melanoma section), CSPG4 up-regulation in MLL leukemia cells is perceived to be a side-product resulting from the deregulated epigenetic regulation inherent to this leukemia subtype.